A new study by the company titled ‘Prothrombin Complex Concentrates Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018–2028’, has listed out the key points being considered by the companies operating in the prothrombin complex concentrates market to emerge and stay sustainably profitable in the long run. The North America prothrombin complex concentrates market is projected to expand at a CAGR of 3.5% over the forecast period. North America and Western Europe are expected to be dominant markets for prothrombin complex concentrates, as most of the manufacturing facilities of prothrombin complex concentrates are located in these regions. However, the increasing demand for optimized & sustainable healthcare in countries of Asia Pacific, such as China and India, and of Middle-East is expected to fuel the growth of the prothrombin complex concentrates market.
The report finds the players operating in the market are laying emphasis on improving treatment options for patients with hemophilia B. Treatment with prothrombin complex concentrates is an economical option for warfarin reversal. It is has been observed that the treatment with prothrombin complex concentrates is the most economical option as it minimizes the hospital stay and laboratory costs. Direct healthcare costs including drug and hospital costs in Europe are approximately US$ 400,000 for prothrombin complex concentrates, whereas for warfarin withdrawal therapy, it was approximated US$ 1,200,000.
To remain ‘ahead’ of your competitors, request for a sample
Manufacturers tend to depend on plasma as a primary precursor to manufacture prothrombin complex concentrates, and in the past, they relied on third-party sources for plasma. Manufacturers are now opening their own plasma collection banks to reduce dependence on third-party sources. This trend has been observed to have grown since 2013. The key players operating in the market, such as CSL Behring & Shire, have scaled up their focus on depending on their own sources for plasma.
Compound pharmacies, retail pharmacies, and hospital pharmacies distributing prothrombin complex concentrates are the primary point of contact for patients experiencing hemophilia B and other disorders. The hospital pharmacies segment in the prothrombin complex concentrates market accounted for over 40% revenue share in 2017. The growing demand for cost-effective diagnostic options is also expected to propel the growth of the global prothrombin complex concentrates market over the forecast period.
The manufacturers of prothrombin complex concentrates are particularly focusing on acquisitions, collaborations, and opening plasma banks, where joint collaboration with various organizations is the prime activity to spread awareness regarding the efficiency of prothrombin complex concentrates.
The growing geriatric population & unmet hemophilia therapeutic needs are also expected to be important factors fueling the growth of the prothrombin complex concentrates market over the forecast period. The worldwide incidence of hemophilia is not well known and it is estimated that 75% of people with hemophilia receive inadequate treatment or have no access to the treatment. The growth in the global population over 65 years of age is expected to be the high impact driver for the growth of the market. As per the U.S. Census Board, around 13% of the U.S. population is above 65 years old and this figure is estimated to touch 20 % by the end of 2030.
Development of prothrombin complex concentrates and commercial production are highly intricate and complex. Prothrombin complex concentrates are prepared from pooled plasma. They pose a theoretical risk of transmitting infectious agents, which might survive the extraction and attenuation steps during the manufacturing process. There is a lack of substantial clinical evidence on contraindications and exclusion criteria, which is expected to hinder the growth of the prothrombin complex concentrates market over the forecast period.
Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-7032
Examples of some of the key participants operating in the prothrombin complex concentrates market analyzed in this report are
- Shire
- Octapharma AG
- Nihon Pharmaceutical Co Ltd
- Sanquin Blood Supply Foundation
- CSL Behring GmbH
- Kedrion Biopharma Inc
- Grifols, S.A.
Additional Questions Answered
Readers can find detailed information about the important positive and negative factors affecting the prothrombin complex concentrates market during the forecast period. Additionally, the report also contains valuable information that can provide prothrombin complex concentrates manufacturers with answers to critical questions, such as
- Which types of products account for the maximum demand for prothrombin complex concentrates market? Why is it so?
- Why is the sale of prothrombin complex concentrates high in North America? What are the factors customers seek in prothrombin complex concentrates?
- Which factors are influencing the strategies of players in the prothrombin complex concentrates market?
- What are the current trends adopted by various companies?
- What are the strategies being applied by the manufacturers in order to sustain themselves in the competitive market?
Segmentation
The report on the prothrombin complex concentrates market provides salient information on market players. The prothrombin complex concentrates market is segmented by region, product type, indication, and distribution channel, to analyze segment-wise growth of the prothrombin complex concentrates market.
Based on regions, the prothrombin complex concentrates market is segmented into seven regions – North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding China & Japan (APECJ), Japan, China, and the Middle East & Africa (MEA). The prothrombin complex concentrates market by product type is segmented into 3-Factor prothrombin complex concentrates, and 4-factor prothrombin complex concentrates.
By indication, the prothrombin complex concentrates market is segregated into hemorrhagic episodes in factor IX defficiency – Haemiohilia B, trauma, life-threatening coagulopathy with acute bleeding, warfarin-associated acute, life threatening bleeding, and non-warfarin anticoagulant reversal with acute bleeding. By distribution channel, the prothrombin complex concentrates market is segregated into compound pharmacies, retail pharmacies, and hospital pharmacies.
For critical insights, request for PDF Brochure: https://www.futuremarketinsights.com/reports/brochure/rep-gb-7032